Get the Stockscreener App
6.785
2.93%
-0.205
Organon Co stock is traded at $6.785, with a volume of 2.85M.
It is down -2.93% in the last 24 hours and down -12.00% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.99
Open:
$7.01
24h Volume:
2.85M
Relative Volume:
0.50
Market Cap:
$1.76B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.5202
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-7.81%
1M Performance:
-12.00%
6M Performance:
-31.32%
1Y Performance:
-53.24%
1-Day Range:
$6.755
$7.04
1-Week Range:
$6.755
$7.39
52-Week Range:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.785 | 1.82B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,063.46 | 932.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
208.53 | 506.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.57 | 396.44B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.10 | 259.09B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.03 | 246.17B | 63.90B | 19.05B | 13.05B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Pharma co Organon inks VPPA with Schneider Electric for solar in Spain - Renewables Now
Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
OGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Organon pushes for sustainable investment in women’s health across Africa - The Business & Financial Times
TetraScience and Organon Collaborate to Modernize Quality Control Data Management - 富途牛牛
Organon Launches Phase 3 Study on Tapinarof Cream for Atopic Dermatitis in Infants - TipRanks
How Investors Are Reacting To Organon (OGN) As Barclays Joins Growing Analyst Skepticism - Sahm
Why Analysts See Organon’s Story Shifting Amid Governance Concerns And Lower Valuations - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon & Co. $OGN Stake Lessened by Globeflex Capital L P - MarketBeat
Organon Shares Under Pressure Following Critical Analyst Review - AD HOC NEWS
Can Organon’s Steep 2025 Share Price Slide Signal a Long Term Opportunity? - simplywall.st
Organon pushes bold women’s health agenda at WHX Leaders’ Summit in Accra - MyJoyOnline
Les billets sont maintenant en vente pour Importance Vitale : sommet national sur la santé des femmes - GlobeNewswire Inc.
Why Organon (OGN) shares are trading lower today - MSN
New York State Common Retirement Fund Sells 353,330 Shares of Organon & Co. $OGN - MarketBeat
Understanding Momentum Shifts in (OGN) - news.stocktradersdaily.com
Investors in Organon & Co. (OGN): Protect Your RightsContact Levi & Korsinsky Before July 22, 2025 - ACCESS Newswire
Organon & Co. (NYSE:OGN) Stock Rating Upgraded by Barclays - MarketBeat
Organon & Co. $OGN Shares Bought by Cerity Partners LLC - MarketBeat
WHX Africa Leaders Summit: Organon Unveils Multi-Sector Approach to Women’s Health in Africa - News Ghana
Barclays Initiates Coverage of Organon (OGN) with Underweight Recommendation - Nasdaq
Why Organon (OGN) Shares Are Trading Lower Today - The Globe and Mail
Organon (OGN) Receives New Coverage with 'Underweight' Rating fr - GuruFocus
Barclays Initiates Coverage on Organon & Co. (NYSE:OGN) - MarketBeat
Norges Bank Takes $19.78 Million Position in Organon & Co. $OGN - MarketBeat
Organon initiated with an Underweight at Barclays - TipRanks
American Century Companies Inc. Grows Position in Organon & Co. $OGN - MarketBeat
What analysts say about Organon Co stockFederal Reserve Announcements & Outstanding Growth Strategies - earlytimes.in
A Closer Look At Organon & Co.'s (NYSE:OGN) Impressive ROE - 富途牛牛
Can Organon (OGN) Turn Rising Investor Attention Into a Durable Reboot of Its Core Story? - simplywall.st
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Co. (7XP) stock compared to peersPortfolio Update Report & Precise Buy Zone Identification - Newser
Organon & Co. $OGN Shares Acquired by Brandes Investment Partners LP - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Russell Investments Group Ltd. Has $15.96 Million Stock Position in Organon & Co. $OGN - MarketBeat
Can Organon’s (OGN) Biosimilar Push Transform Its Competitive Position in US Oncology? - Yahoo Finance
A Look at Organon's Valuation Following FDA Approval of First US Pertuzumab Biosimilar - Yahoo Finance
Is Organon’s Recent 14% Price Jump Justified After Women’s Health Partnership News? - Yahoo Finance
What analysts say about Organon Co 7XP stockShort Interest Overview & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? - The Globe and Mail
Grantham Mayo Van Otterloo & Co. LLC Buys 108,429 Shares of Organon & Co. $OGN - MarketBeat
Avoiding Lag: Real-Time Signals in (OGN) Movement - news.stocktradersdaily.com
Organon (OGN): Exploring Valuation Following FDA Approval of First US Pertuzumab Biosimilar - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Organon & Co. $OGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Creative Planning Buys 97,429 Shares of Organon & Co. $OGN - MarketBeat
Advisors Asset Management Inc. Sells 64,625 Shares of Organon & Co. $OGN - MarketBeat
Is Organon Co 7XP a good long term investmentLong-Term Investment Plans & High Yield Investment Portfolio - earlytimes.in
Organon & Co. $OGN Shares Sold by Geode Capital Management LLC - MarketBeat
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):